INTRODUCTION
============

BAC and PAC clones have become the preferred tool for generating transgenic animals, since they accommodate large genomic DNA fragments, are well characterized, stable and easy to propagate and purify. In recent years, efficient and reliable methods have been developed to modify their sequence in *E. coli*. These techniques are generally termed recombineering (homologous recombination-mediated genetic engineering) and they are based on homologous recombination between a linear double-stranded DNA cassette or synthetic oligonucleotides and a circular DNA molecule (plasmid, BACs or PACs) ([@B1],[@B2]). A variety of methods and strains have been described for homologous recombination, but the most widely used methods derive the homologous recombination machinery from the bacteriophage λ-encoded Red system ([@B3]). The DY380 strain of *E. coli* is derived from DH10B and encodes a defective λ-prophage, in which the recombination apparatus is expressed under the control of the temperature-sensitive λ repressor (*cI857*) ([@B3],[@B4]). Two further strains have been derived from DY380 in which the tetracycline resistance gene, (encoded on the bacterial genome) is substituted by either *Flp* (strain EL250) or *Cre* (strain EL350) genes ([@B5]). The *Flp* or *Cre* genes are expressed under the control of the arabinose-inducible *AraC-P~BAD~* promoter to allow further manipulation of introduced BAC/PACs. Cre DNA recombinase catalyses the recombination between two 34-bp *lox*P elements. The outcome (excision or inversion) depends on the relative orientation of the 2 *lox*P elements ([@B6]). The *lox*P element contains a core spacer sequence of 8-bp flanked by two palindromic sequences each of 13-bp to which Cre binds ([@B7]). Up to 5 mismatches from the consensus in each of the two palindromic sequences can be tolerated by Cre, without significantly reducing DNA binding ([@B8],[@B9]). The core sequence is the cleavage site; its asymmetry defines the direction of the *lox*P site and homology in this region between two *lox*P sites is required for efficient recombination ([@B10]). When recombination occurs between a mutant *lox*P site, which bears a deletion in the spacer region, and a wild-type *lox*P site, the introduction of single- and double-strand breaks in the DNA may occur ([@B11]). On a statistical basis, the 34-bp consensus *lox*P site is not expected to be present in mammalian genomes, but the presence of functional recombinase recognition sites, that diverge significantly from the native *lox*P site, has been identified in both the human and mouse genomes ([@B12]). These cryptic (or pseudo) *lox*P sites, can support Cre-mediated recombination at high efficiency when cryptic *lox*P sites with the same spacer region are involved in the recombination ([@B12]). Studies have shown that Cre expression in mammalian cells causes recombination events between cryptic *lox*P sites resulting in gross chromosomal rearrangements in spermatids ([@B13]) and, in cultured mammalian cells, growth inhibition accompanied by DNA damage ([@B14]). Furthermore, recombination can occur even when the spacer regions display a relatively high level of non-homology ([@B15]). Moreover, it is generally acknowledged that some large DNAs grow slowly in Cre-containing *E. coli* and it has been reported that modified strains of *E. coli* are not ideal for receiving PACs and BACs and some BAC clones cannot be transformed into such strains for reasons that are not fully understood ([@B16]).

Our hypothesis is that cryptic *lox*P sites, encoded in the mammalian genomic DNA insert, may act as substrates for Cre recombinase, expression of which may be leaky in some bacterial strains.

Here, we describe the use of a bioinformatics tool to identify such cryptic sites and experiments to test these predictions carried out on BAC/PACs.

MATERIAL AND METHODS
====================

*In silico* identification of cryptic *lox*P sites
--------------------------------------------------

To automate the identification of cryptic *lox*P sites within a given DNA sequence a bioinformatics workflow was created using Taverna \[TAVERNA\] ([@B17]). Taverna provides a workbench application that enables the construction and enactment of workflows within a graphical environment. A schematic representation of the workflow is illustrated in [Figure 1](#F1){ref-type="fig"}. This workflow takes a DNA sequence and searches for matches to three different patterns using Fuzznuc, which is freely available as part of the European Molecular Biology Open Software Suite (EMBOSS) \[EMBOSS\] ([@B18]) and is accessed via a Soaplab \[SOAPLAB\] web service ([@B19]). Figure 1.Schematic representation of the workflow created to automate the identification of cryptic *lox*P sites.

Pattern 1 is described by the sequence ATAACTTCGTATA (N)~8~ TATACGAAGTTAT ([@B12]) and it selects for high homology in the 13-bp palindromic regions of the wild-type *lox*P. This pattern is augmented by a mismatch parameter that allows up to 10 mismatches to be tolerated ([@B8],[@B9]). Pattern 2 is described by the sequence ATNAC(N)~2~CNTATA (N)~8~ TATANG(N)~2~GTNAT. It selects for conservation of those base pairs in the *lox*P site believed to be contact points for the *Cre* enzyme (underlined bases in the sequence [AT]{.ul}A[AC]{.ul}TT[C]{.ul}G[TATA]{.ul} ATGTATGC [TATA]{.ul}C[G]{.ul}AA[GT]{.ul}T[AT]{.ul}). This pattern is augmented by a mismatch parameter that allows up to 5 mismatches to be tolerated. We hypothesized that the mismatches allowed in this search could be tolerated by the *Cre* recombinase. Pattern 3 is described by the sequence (N)~9~TATA (N)~8~ TATA(N)~9~. It ensures that the TATA motif surrounding the core 8-bp spacer region is present. This pattern is augmented by a mismatch parameter that ensures no mismatches are tolerated. The fulfilment of these three criteria defines a primary cryptic *lox*P site and provides a wider classification then previously proposed ([@B12]).

A web service called FuzznucComparator was developed that compares the output from two Fuzznuc processes and outputs only those sequences present in both. When the result of the comparison contains more than one sequence, the FuzznucComparator tool performs 2 pairwise alignments of the core 8-bp spacer regions. The first alignment is calculated using the sequences in their given orientation. The second complements one sequence prior to making the alignment. The output file format consists of the result of the pairwise comparison (if any) followed by those sequences present in both input files in fuzznuc\'s seqtable format.

To isolate those sequences that match all three patterns two comparisons are required. First, a FuzznucComparator process is used to isolate those sequences that match patterns 1 and 2. A fileDivider process splits the output content and outputs only the fuzznuc seqtable section. Second, a FuzznucComparator process compares the output from the fileDivider process with those sequences that match pattern 3. The final step in the workflow is to write those sequences that match all three patterns to file. The Scufl workflow can be downloaded from <http://www.bioinf.mvm.ed.ac.uk/projects/workflows/loxp>. This workflow can be opened and enacted within the Taverna workbench. A web page interface to this workflow is also freely available at: <http://wilkie226.dmed.ed.ac.uk:8080/loxpFinder>.

The default mismatch values enable discovery of primary cryptic *lox*P sites. The Taverna workbench and the web page interface enable users to edit the workflow and thus change the number of mismatches tolerated for each pattern. By relaxing the number of allowed mismatches the workflow can find secondary cryptic *lox*P sites. Additional information regarding how to use these resources is available in the online manual.

Plasmid, BAC/PAC vectors, *E. coli* strains and growth conditions
-----------------------------------------------------------------

pROSA26/Tet is a pBluescript-modified plasmid containing a tetracycline resistance gene sub-cloned between two *lox*P consensus sequences (pROSA26 unpublished, personal gift from Yuri Kotelevtsev, University of Edinburgh. Original source Igor Samokhvalov, RIKEN Center for Developmental Biology, Kobe Japan). This plasmid contains no *AraC*-*P~BAD~* promoter elements.

PAC111L11 ([@B20]) (kindly provided by Craig A. Jones, Buffalo, New York) maps on human chromosome 1 and spans the *Ren* gene locus. The vector backbone (pCYPAC2) contains a single consensus *lox*P site and encodes kanamycin resistance. BACN10 was isolated by the screening of a mouse genomic library (129/Ola mouse strain) (Invitrogen Corporation, Formally Research Genetics) using a renin gene probe. It maps on mouse chromosome 1 and spans the *Ren1^c^* and *Ren1^d^* gene locus. The vector backbone (pBeloBAC11) contains a single *lox*P site and encodes chloramphenicol resistance. ASBAC (kindly provided by Keith Parker Dallas, Texas) also comes from a pBeloBAC11 library, and maps to chromosome 15, spanning the *cyp11b1* and *cyp11b2* genes. \[BAC ends coordinates refer to RP23-23009 clone sequence T7: 205723 bp, SP6: 82689 bp\]. The DY380, EL250 and EL350 strains of *E. coli* have been described ([@B3]), and were kindly provided by Neal Copeland (Mouse Cancer Genetics Program, National Cancer Institute-Frederik).

EL350 and EL250 differ from DY380 in that they encode the *Cre* and *Flp* recombinase genes respectively under the control of *AraC*-*P~BAD~* promoter and they are not tetracycline resistant ([@B5]).

One hundred nanograms of PAC or BAC DNA were transformed into EL350 and DY380 bacterial strains by electroporation (Easyjet Plus, Equibio; 1.75 kV, 200 ohms, 2 μF). Following selection on kanamycin/chloramphenicol plates, a 10^−6^ dilution of cells was plated on LB agar plates containing either 0.2% arabinose or 0.2% glucose and incubated overnight at 32°C.

*In vivo* assay for *Cre* activity in EL350
-------------------------------------------

EL350 cells were transformed with 40 ng of pROSA26/TET plasmid DNA by electroporation and plated on LB agar containing 50 μg/ml ampicillin or 25 μg/ml tetracycline or both antibiotics. After overnight growth at 32°C, colonies were counted and the ratio of tetracycline-resistant colonies to ampicillin-resistant colonies calculated as a measure of the *Cre* gene expression in EL350 in the un-induced state. This measure was then compared to the *Cre* activity after induction of the P~BAD~-promoter with 0.1% arabinose, according to a protocol adapted from Lee *et al.* (2001) ([@B5]) which is available at <http://recombineering.ncifcrf.gov/Protocol.asp>. Two cell dilutions (10^−4^ and 10^−6^) were plated on *Amp, Amp/Tet* and *Tet* plates.

*In vitro* assay for BAC/PAC DNA nicking
----------------------------------------

One microgram of BAC/PAC DNA extracted from DY380 cells was incubated with 1 or 2 μl of Cre enzyme (1000 U/ml, New England Biolabs) overnight. After the incubation, each reaction was phenol-chloroform extracted and ethanol precipitated. An aliquot of DNA was then digested with *Eco*RV or *Hin*dIII restriction enzymes (Promega). DNA, re-suspended in alkaline gel loading buffer (50 mM NaOH, 1 mM EDTA, 2.5% Ficoll and 0.025% bromoCresol green), was loaded on a denaturing gel as previously described ([@B21]). Following electrophoresis, the gel was soaked in 0.25 N HCl for 6--7 min, rinsed and neutralised in 0.5 N NaOH, 1.5 M NaCl for 30 min, blotted onto a positively charged membrane and hybridized according to standard procedures with specific radiolabelled probes, generated using the Ready-To-Go™ DNA Labelling beads (Amersham Pharmacia Biotech). Probes P1 (for the detection of cryptic *lox*P site 1) P2 and P3 (to detect cryptic *lox*P site 2) were generated by PCR from the PAC111L11 clone, using primers c-*lox*P1F 5′-CTCAGACACTTTGGTGGGTC-3′ and c-*lox*P1R 5′-GACTTTCAGTATGGCTGCCTAAC-3′ for probe 1 (P1); c-*lox*P2F 5′-CAGGAGTTAGAGACCAGC-3′ and c-*lox*P2R 5′-GCTATCTCGGCTCACTG-3′ for probe 2 (P2) and c-*lox*P3F 5′-GAAGGGCTGAGGTTAGGCAG-3′ and c-*lox*P3R 5′-GAACACCTACTGAGCTTGAG-3′ for probe 3 (P3).

RESULTS
=======

Mouse genome-wide distribution of cryptic *lox*P sites
------------------------------------------------------

In order to assess the distribution and frequency of cryptic *lox*P sites in the genome, a new bioinformatics tool (FuzznucComparator) was developed to perform a mouse genome-wide search (see materials and methods). Two stringencies were applied. Primary cryptic *lox*P sites were identified as sequences conforming to three patterns, which together define a primary cryptic *lox*P site (homology in the 13-bp palindromic sequences of the *lox*P consensus sequence; conservation of base pairs in the *lox*P site believed to be contact points for the *Cre* enzyme and presence of the four bases (TATA) flanking the core sequence). [Figure 1](#F1){ref-type="fig"} shows the workflow for the search of cryptic *lox*P sites. FuzznucComparator also defined secondary cryptic *lox*P sites, using less stringent criteria where the mismatch allowance for the three patterns is increased arbitrarily by the operator. In our hypothesis, some of these secondary sites have the potential to bind Cre and mediate DNA damage, if they are located near primary cryptic *lox*P sites.

The NCBI m34 mouse assembly (<http://www.ncbi.nlm.nih.gov/genome/seq/NCBIContigInfo.html>) was split into one-megabase regions and submitted to the Fuzznuc and FuzznucComparator search for the three patterns defining a primary cryptic *lox*P site. The output of the search is represented in [Figure 2](#F2){ref-type="fig"}. The overall frequency of primary cryptic *lox*P sites in the mouse genome is 1.2 per megabase. Some chromosomes show a more tightly clustered distribution of cryptic *lox*P sites than others ([Figure 2](#F2){ref-type="fig"}, Chr 3, 13, 14, 15, 16, 18 and X). A few chromosomes ([Figure 2](#F2){ref-type="fig"}, Chr 1, 2, 4, 7, 16) present with hot spots of cryptic *lox*P sites, generally 8 or 9 in a Mb DNA window, but up to 17 in the case of chromosome 1. Chromosome Y has no primary cryptic *lox*P sites. Figure 2.Mouse genome-wide search for cryptic *lox*P sites. Each graph shows the distribution and the number of cryptic *lox*P sites in 1 Mb regions along the 21 mouse chromosomes. The length of each graph is proportional to the corresponding chromosomal length. A megabase scale is present at the bottom of each graph.

About 10% of the spacer regions in primary cryptic *lox*P sites are not unique, and occur more than once.

*In silico* identification of cryptic *lox*P in PAC/BAC sequences
-----------------------------------------------------------------

Three BAC and PAC clones (BACN10, ASBAC and PAC111L11) were scanned for cryptic *lox*P sites (in addition to the consensus *lox*P site in the backbone of their respective vectors) to see whether their presence caused instability in Cre-expressing host cells. Both PAC111L11 and BACN10, which span the human and mouse renin locus respectively, show the presence of primary cryptic *lox*P sites that match all three patterns. The search returned two potential cryptic *lox*P sequences (c-*lox*P1 and c-*lox*P2) in PAC111L11 with 5 out of 8 bp matching in the spacer region (62.5% identity) ([Table 1](#T1){ref-type="table"}). A search for secondary cryptic *lox*P sites within 6 kb of each primary site revealed one hit (sc-*lox*P), located 4.3 kb upstream of c-*lox*P2 in PAC111L11. The sc-*lox*P has twelve mismatches to the consensus *lox*P in the 13-bp palindromic arms, 12 out of 18 conserved Cre contact points and 3 mismatches in the TATA sequences flanking the spacer region. When aligned with the complementary strand of the c-*lox*P2 site, 4 out of 8 bp match in the spacer region. Table 1.Number of primary cryptic *lox*P sites in three BAC/PAC molecules and their characteristicsPAC/BAC namePutative primary cryptic *lox*P sites (search pattern1 and 2)Pairs of primary c-*lox*P sites with 6/8 matches in the spacer regionPairs of primary c-*lox*P sites with 5/8 matches in the spacer regionPairs that have conservation in the 4 bases flanking the spacer regionPAC111L11(H)2011ASBAC (M)5010BACN10 (M)4112

BACN10 is predicted to contain four primary cryptic *lox*P sites. Two of these are identical at 6 out of 8 bp in the spacer region and the other two match at 5; both pairs of sites show conservation in the four bases flanking the spacer region ([Table 1](#T1){ref-type="table"}). A search for secondary cryptic *lox*P sites in the regions surrounding the primary sites returned one hit with the same characteristics outlined for the sc-*lox*P site in PAC111L11.

ASBAC contains 5 sequences that match the first two criteria for primary cryptic *lox*P sites but, when considered in pairs, none show conservation in the four bases flanking the core region ([Table 1](#T1){ref-type="table"}). Since not all three criteria for cryptic *lox*P definition are satisfied, these sites are not predicted to be functional.

Differential growth of PAC/BAC-transformed EL350 *E. coli* strain compared to DY380 and EL250
---------------------------------------------------------------------------------------------

To test the hypothesis that cryptic *lox*P sites mediate DNA damage in *E. coli* strains expressing Cre recombinase, PAC111L11 (depicted in [Figure 3](#F3){ref-type="fig"}) was transformed into DY380 (expressing neither Cre nor Flp), EL250 (expressing Flp) and EL350 (expressing Cre) *E. coli* ([@B3]). Transformed cells were grown in the presence of arabinose (to induce the *AraC*-*P~BAD~* promoter) or glucose (to ensure catabolite repression of the promoter) ([@B22; @B23; @B24]). Whilst the growth of PAC111L11-transformed DY380 and EL250 cells was similar on plates containing glucose or arabinose ([Figure 4](#F4){ref-type="fig"}B and C), the growth of PAC111L11-transformed EL350 cells differed on arabinose, with a similar number of colonies of much smaller size ([Figure 4](#F4){ref-type="fig"}A). Statistically significant reduced colony diameter is observed on arabinose plates when comparing PAC111L1-transformed EL350 (colony diameter 0.51 ± 0.02 mm) cells to PAC111L11-transformed DY380 (colony diameter 1.69 ± 0.02 mm on arabinose, p \< 0.001) or EL250 (colony diameter 1.44 ± 0.02 mm on arabinose, p \< 0.01) cells. In addition, the EL350-PAC111L11 colonies formed in the presence of glucose were appreciably smaller than those formed by DY380 or EL250 transformants. The effect of glucose on PAC111L11-transformed EL350 colony size is concentration-dependent with 1% glucose resulting in the largest colonies ([Figure 5](#F5){ref-type="fig"}). Un-transformed DY380 and EL350 cells grow with the same efficiency in 0.2% arabinose-containing agar, despite the presence of one primary cryptic *lox*P site in the *E. coli* bacterial genome ([Figure 5](#F5){ref-type="fig"}, inset). Figure 3.(**A**) Positions of the cryptic *lox*P sites on the PAC111L11 insert. (**B**) Sequence comparison between the *lox*P consensus site and PAC111L11 cryptic *lox*P sites (primary c-*lox*P and secondary sc-*lox*P). Underlined nucleotides --- Cre contact points on *lox*P consensus sequence; bold --- conserved nucleotides. Figure 4.Growth of PAC111L11-transformed EL350 (**A**), DY380 (**B**) and EL250 (**C**) cells on LB agar supplemented with either 0.2% glucose or 0.2% arabinose. Arrows indicate very small and barely detectable colonies formed on arabinose-containing agar by EL350/PAC111L11. Figure 5.Growth of PAC111L11-transformed EL350 on LB agar supplemented with increasing concentrations of glucose. Inset: Un-transformed EL350 and DY380 on agar with 0.2% arabinose.

EL350 cells transformed with BACN10 also gave rise to very small colonies that failed to grow or had delayed growth on arabinose (data not shown), whereas EL350 cells transformed with ASBAC showed no difference in growth rate.

*In vivo* assay for Cre activity in EL350
-----------------------------------------

Low levels of expression from the P~BAD~ promoter can occur in the absence of the inducer arabinose if the expression at maximum induction is very high. Leaky *Cre* expression from the *AraC*-*P~BAD~* promoter has been described for multi-copy plasmids ([@B25]). However, in EL350 cells the *AraC*-*P~BAD~*-Cre gene is present in a single copy. To test if *Cre* was produced from the un-induced *AraC-P~BAD~* promoter in EL350, a functional test was performed, using a plasmid vector (pROSA26/Tet) encoding a tetracycline resistance gene between two *lox*P consensus sequences ([Figure 6](#F6){ref-type="fig"}A). The plasmid pROSA26/Tet also confers ampicillin resistance to the host. If recombination occurs between the *lox*P sequences, the *Tet* resistance gene is excised and the *E. coli* strain can only grow under *Amp* selection. This was the case when *Cre* expression in EL350 cells was induced with arabinose. Two cell dilutions (10^−4^ and 10^−6^) were plated on LB agar plates containing either 50 μg/ml ampicillin or 25 μg/ml tetracycline or both. Although many colonies were obtained on ampicillin, no colonies were observed on *Amp/Tet* or *Tet* plates ([Figure 6](#F6){ref-type="fig"}B), even after 24 h. Following transformation with pROSA26/Tet, *Tet* resistant colonies were obtained in the absence of arabinose (when the *AraC-P~BAD~* promoter is not induced in EL350 cells), however, the number of colonies was reduced approximately twenty-fold ([Figure 6](#F6){ref-type="fig"}B). These data show that about 95% of the colonies that are able to grow on an *Amp/Tet* plate have lost the tetracycline gene and are no longer able to grow under tetracycline selection (p \< 0.01). In order to verify if all the plasmid molecules inside a single *E. coli* colony have undergone site-specific recombination or a few of them retain the tetracycline resistance gene, a PCR assay was performed on colonies using primer T3 and T7 ([Figure 6](#F6){ref-type="fig"}C). A mixed plasmid population (excised and non-excised) is recovered from un-induced EL350. This is shown by the presence of two DNA fragments, one of 1.5 Kb (*Tet* retaining plasmids) and one of 0.2 Kb (*Tet* excised plasmids). After induction of EL350 with arabinose, the tetracycline resistance gene was found to be 100% excised. Plasmids that grow into DY380 do not show any sign of site-specific recombination and maintain the tetracycline resistance gene ([Figure 6](#F6){ref-type="fig"}C, right panel). Figure 6.(**A**) pROSA26/Tet plasmid map. (**B**) Summary of the transformation of pROSA26/Tet plasmid into EL350. (**C**) PCR analysis of pROSA26/Tet transformed EL350 and DY380 under arabinose-induced and un-induced conditions using T3 and T7 primers. M1: 1 Kb Marker (New England Biolabs). M2: pBluescriptII SK+ plasmid digested with Sau3AI. The 1.5 Kb band indicates the presence of the *Tet* gene; the 0.2 Kb band is generated after Cre/*lox*P-mediated excision of the *Tet* gene.

Analysis of nicks in PAC111L11 DNA after incubation with Cre
------------------------------------------------------------

The ability of Cre recombinase to introduce single or double-strand nicks at cryptic *lox*P sites was tested by incubation with PAC111L11 DNA. DNA fragments produced by the action of Cre were detected by Southern blot following either *Hin*dIII or *Eco*RVV restriction digest for the analysis of c-*lox*P1 nicks or c-*lox*P2 nicks, respectively using a c-*lox*P1 specific probe (P1) or c-*lox*P2 specific probes (P2 and P3; [Figure 7](#F7){ref-type="fig"}). Figure 7.*In vitro* analysis of the presence of nicks in PAC111L11 insert. (**A**) Schematic representation of expected fragment size for DNA nicked at cryptic *lox*P1 site. The arrow indicates the location of the c-*lox*P1 site on the *Hin*dIII fragment. P1: probe 1. (**B**) Schematic representation of predicted fragment sizes for DNA nicked at the c-*lox*P2 and secondary sc-*lox*P sites on the *Eco*RVV fragment. Arrows indicate the location of the c-*lox*P2 and sc-*lox*P sites, P2 --- probe 2, and P3 --- probe 3. (**C**) Southern analysis of PAC111L11 DNA, following overnight incubation with Cre recombinase, digested with *Hin*dIII and hybridized to probe P1 to detect nicks produced at the c-*lox*P1 site. M:1 kb DNA ladder (NEB) Plus and minus signs on each lane refer to the presence or absence of Cre recombinase and its relative abundance. (**D**) and (**E**) Southern analysis of PAC111L11 DNA, following overnight incubation with *Cre* recombinase, digested with *Eco*RVV and hybridized with probe P2 (D) and P3 (E) to detect nicks produced by cryptic *lox*P site 2 and/or sc-*lox*P. M:1 kb DNA ladder (NEB) Plus and minus signs on each lane refer to the presence or absence of Cre recombinase and its relative concentration.

PAC111L11 DNA showed no evidence of nicking or cleavage at c-*lox*P1 following overnight incubation with Cre recombinase ([Figure 7](#F7){ref-type="fig"}C). Only one band of 3.5 kb, corresponding to the intact DNA, was detected by probe P1. In contrast, hybridization of probes P2 and P3 to *Eco*RVV-digested PAC111L11 DNA detected fragments consistent with cleavage at both c-*lox*P2 and sc-*lox*P sites ([Figure 7](#F7){ref-type="fig"}D and E). In the absence of Cre, the expected 6.6 kb fragment produced by *Eco*RVV digestion of intact PAC111L11 DNA was detected. At the higher concentration of Cre, additional fragments of 4.3 kb (with probe P2, [Figure 7](#F7){ref-type="fig"}D) and 0.9 kb (with probe P3, [Figure 7](#F7){ref-type="fig"}E) were detected.

These results suggest that the primary (c-*lox*P2) and the secondary (sc-*lox*P) c-*lox*P sites that map in the PAC111L11 insert are able to bind Cre recombinase enzyme and start a recombination event, which is non-productive and results in damage to the PAC DNA molecule.

The absence of the nicked 2.9 kb at the c-*lox*P1 site and 5.7 kb at the c-*lox*P2 site suggests that these cryptic *lox*P site are not getting paired and defectively recombined with the proper consensus *lox*P site that is located in the backbone of the PAC sequence.

DISCUSSION
==========

Although little evidence has been reported, certain BAC/PAC inserts are difficult to propagate in Cre-containing *E. coli* strains. It is possible this could be due to low levels of Cre promoting single strand DNA breaks or recombination through cryptic *lox*P sites present in the inserts. Computational analysis of the whole mouse genome has revealed an average of 1.2 primary cryptic *lox*P sites per Mb DNA, with few hotspots present (chromosome y has none). The new bioinformatic tool, FuzznucComparator has been made available through a Distributed Annotation System (DAS) resource to enable dynamic access to the data using http requests (i.e. a URL), with the response being returned as XML. This resource is implemented using a Dazzle \[DAZZLE\] server backed by an LDAS database and can be accessed at: <http://wilkie226.dmed.ed.ac.uk:8080/das>. Access via the DAS protocol also allows these annotations to be viewed as a track within Ensembl (Ensembl help, <http://www.ensembl.org/Homo_sapiens/helpview?se?1;kw?dasconfview>, documents how to achieve this).

We have tested the power of the programme to predict functional cryptic *lox*P sites in the genomic insert of BAC and PAC sequences, which could potentially affect their growth in Cre recombinase expressing *E. coli* strains. We have identified primary and secondary cryptic *lox*P sites in the genomic insert of three BAC/PAC clones and shown that these are substrates for Cre recombinase *in vitro*. Furthermore, following transformation into EL350 cells, they demonstrate a dramatically reduced growth rate in the presence of arabinose, compared to DY380 and EL250. The poor growth is ameliorated by glucose suggesting a Cre-mediated effect on bacterial growth. We suggest that, since Cre recombinase is leaky, EL350 has a growth defect when transformed with PAC111L11.

Despite the higher conservation level of c-*lox*P1 and c-*lox*P2, our data shows that c-*lox*P2 and sc-*lox*P are involved in the single-strand nicking of PAC111L11, incubated *in vitro* with Cre recombinase. c-*lox*P2 and sc-*lox*P are located relatively close to each other, whereas c-*lox*P1 lies 70 kb away from c-*lox*P2. The interaction of Cre recombinase with cryptic *lox*P sites is likely to be weaker than with genuine *lox*P sites. However, proximity of two cryptic *lox*P sites may serve to increase the local concentration of Cre recombinase, increasing the likelihood of DNA nicking at one or both sites.

All three BAC/PAC molecules we have analysed contain a *lox*P consensus sequence in their respective vector backbones. However, we consider it unlikely that they mediate nicking for the following reasons: ([@B1]) they occur in most if not all BAC/PAC vectors and clearly DNA nicking and poor growth is not a problem with all BAC/PACs. ([@B2]) ASBAC also encode putative cryptic *lox*P sites, however, their presence did not result in slower growth in EL350 cells than EL250 or DY380 cells. We cannot exclude that in other molecules DNA damage might occur if the conditions (homology in the spacer region and location of the c-*lox*P site close to the end of the insert, and thus proximal to the genuine *lox*P site) are favourable. These data provide a functional definition of active cryptic *lox*P sites; more relaxed mismatches allowance in comparison to the criteria previously set ([@B12]) shows that a high degree of deviation from the *lox*P consensus sequence is still tolerated by *Cre* recombinase.

The demonstration that Cre recombinase expression is leaky in this strain supports the hypothesis that the damaged PAC DNA fails to replicate, depriving the *E. coli* daughter cells of the selectable marker. These findings are in accordance with data in the literature that show that mammalian genomes contain active recombinase recognition sites ([@B12]) and that growth inhibition and DNA damage can be induced by the expression of Cre recombinase in mammalian cells, *E. coli* and yeast ([@B14],[@B26; @B27; @B28]). The leakiness of Cre recombinase in EL350 cells is not surprising. Studies have demonstrated that P~BAD~ promoters are very efficient, but the levels of repression are not always zero, because they are relative to the levels of expression at maximum induction ([@B25]).

During cleavage, Cre becomes covalently attached to the DNA through a 3′-phosphate. This type of covalent protein-DNA linkage is very similar to that observed with DNA topoisomerases ([@B11],[@B29; @B30; @B31]). In the presence of cryptic *lox*P sites or mutant *lox*P sites ([@B11]), *Cre* protein attempts to carry out recombination, but the reaction is abortive. If the reaction progresses to the stage where nicks are introduced into the DNA, then a damaged DNA molecule is produced, which is covalently linked to a protein making it very difficult to repair by the cell repair machinery ([@B32]).

Many lines of transgenic mice have been generated that express Cre recombinase, but there are few reports of adverse effects of this protein *in vivo*. The potential for DNA damage is demonstrated by the infertility of transgenic mice expressing Cre in spermatids, due to illegitimate Cre-dependent chromosome rearrangements ([@B13]). It is possible that somatic mutations remain undetected, due to the high tolerance of mammals for somatic cell death and, in light of this study, a more detailed analysis of the phenotype of transgenic animals bearing the *Cre* recombinase gene may be informative.

Finally, these results suggest that the presence of cryptic *lox*P sites in BAC/PAC inserts can affect the efficiency of recombineering techniques if the host cells express Cre recombinase even in a leaky way. This problem is BAC/PAC dependent and does not diminish the usefulness of recombineering techniques. Nevertheless, these data propose and describe a mechanism, which explains why recombineering experiments sometimes don't give the expected results and provide a bioinformatic tool, which can alert and guide in the planning process. The use of FuzznacComparator to identify cryptic *lox*P sites in BAC/PAC inserts may be helpful in determining which BACs may prove to be most manipulatable with the *Cre/*lox*P* system.
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